Delcath Systems Inc (DCTH)

[DesertEagle]

An idiom from the Old Testament: A leopard can't change its spots. A person cannot change who they are (their character), no matter how hard they try.

There is no doubt that clinically the company is functioning, the results in the European Union are a testament to that.

There is no doubt that Ms. Simpson knows her business "clinically"... takes some smarts, hard work and dedication to get a PhD., M.S.N. and C.R.N.P. behind your name.

The problem is not with the clinical side of the company, it is with the business side. They are making very poor choices to support the clinical side (Chemosat) and the public (investors) that own the company.

In my opinion, they have not engaged the shareholders, many of who believe in the benefits of their R&D. Had they done this, they would have been surprised at the amount of support many would have given them.

Rather then going back to the same trough for financing, why have they not done a follow-on public offering? With the PH3 interim safety analysis complete, if the data is correct and everything is on track, a follow-on public offering could be done successfully with a good management team and proper IR/PR.

Why have they not looked at other sources of private financing. It is out there if they would only engage but that might involve actually doing some work and thinking outside the box.

That fact that not one of the Management Team or Board of Directors have made an open market purchase of the company's stock in many years indicates that even they do not have faith in each others ability to right this ship called Delcath.

If you are a shareholder I wish you luck.

DE